Table 3. Prediction of occurrence of atrial fibrillation stratified by gender and age.

	Male		Female		<65		> = 65
	cHRs (95% C.I.)	p-value	aHRs (95% C.I.)	p-value	cHRs (95% C.I.)	p-value	aHRs (95% C.I.)	p-value
Gout vs. matched	1.41 (1.29–1.55)	<0.0001	1.29 (1.12–1.48)	0.0005	1.62 (1.42–1.84)	<0.0001	1.25 (1.14–1.38)	<0.0001
Age	1.33 (1.06–1.65)	0.0121	1.08 (0.79–1.48)	0.6185	1.36 (1.00–1.84)	0.0477	1.17 (0.93–1.47)	0.1776
Comorbidities
DM	0.98 (0.81–1.19)	0.8333	1.47 (1.16–1.85)	0.0013	1.37 (1.04–1.80)	0.0233	1.05 (0.88–1.25)	0.6184
CKD	1.77 (1.08–2.91)	0.0239	0.97 (0.53–1.78)	0.9271	3.01 (1.12–8.10)	0.0291	1.27 (0.82–1.95)	0.2849
HTN	1.21 (1.05–1.40)	0.0101	1.31 (1.06–1.62)	0.0114	1.35 (1.10–1.67)	0.0049	1.15 (0.99–1.33)	0.0659
COPD	1.01 (0.79–1.29)	0.9496	0.87 (0.56–1.35)	0.5330	1.08 (0.60–1.97)	0.794	0.98 (0.78–1.23)	0.8423
CAD	1.57 (1.32–1.87)	<0.0001	1.43 (1.13–1.79)	0.0026	1.59 (1.20–2.12)	0.0014	1.50 (1.28–1.77)	<0.0001
HCPS*	1.99 (0.37–10.69)	0.4203	—		—		2.13 (0.41–11.06)	0.3673
AI^	1.76 (0.50–6.19)	0.3823	—		0.90 (0.19–4.38)	0.8997	4.17 (0.44–39.45)	0.2132
Sleep apnea	1.45 (0.37–5.66)	0.5964	—		1.00 (0.14–7.46)	0.9986	1.23 (0.20–7.48)	0.8211
CHF	3.40 (2.48–4.68)	<0.0001	2.21 (1.58–3.10)	<0.0001	9.90 (4.13–23.75)	<0.0001	2.37 (1.85–3.02)	<0.0001
RA	0.84 (0.41–1.74)	0.6408	1.16 (0.57–2.36)	0.6745	1.39 (0.60–3.23)	0.4378	0.88 (0.46–1.68)	0.7016
SLE	0.73 (0.10–5.27)	0.7534	—		2.20 (0.19–25.66)	0.5299	1.60 (0.13–20.22)	0.7146
Scleroderma	—	—	—		0.46 (0.02–10.61)	0.6272
SS&	1.00 (0.30–3.29)	0.9995	1.36 (0.36–5.18)	0.6485	0.42 (0.10–1.85)	0.2522	1.64 (0.59–4.54)	0.3394

The statistical analysis was performed with the Cox proportional hazards regression model to indicate significance (at p < 0.05 level).

aHRs: adjusted hazard ratios; cHRs: crude hazard ratios; CI: confidence interval; AI^: alcoholic intoxication; HCPS*: history of cardiac or pulmonary surgery; SS&: Sjögren’s syndrome; other abbreviations are as described in Table 1.